Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy VI: Nursing Management

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France.

Orphanet journal of rare diseases·2025

Same author

Cancer therapy-related cardiac dysfunction after radiation therapy for breast cancer: results from the BACCARAT cohort study.

Cardio-oncology (London, England)·2024

Same author

The D-HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy.

ESC heart failure·2024

Same author

Identification of Prominin-2 as a new player of cardiomyocyte senescence in the aging heart.

Aging cell·2024

Same author

Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019).

Revue neurologique·2024

Same author

[Preeclampsia: A challenge also for cardiologists].

Annales de cardiologie et d'angeiologie·2018

Search research articles

Related Experiment Video

Updated: Jan 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

[Hypertrophic cardiomyopathies].

¹Fédération médico-chirurgicale de cardiologie, CHU Rangueil, 1, avenue Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France; Centre d'imagerie cardiaque, CHU de Toulouse, 31000 Toulouse, France; Faculté de médecine Toulouse - Purpan, université Paul-Sabatier, 31000 Toulouse, France.

La Revue De Medecine Interne

|February 12, 2019

Summary

Hypertrophic cardiomyopathies involve diverse causes leading to left ventricular hypertrophy. Early diagnosis and tailored treatments, including genetic analysis, are crucial for managing this complex heart condition.

Keywords:

Amyloidosis Amylose Cardiomyopathie hypertrophique Genetic Génétique Hypertrophic cardiomyopathy Hypertrophie ventriculaire gauche Left ventricular hypertrophy Sarcomeric Sarcomérique

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jan 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Area of Science:

Cardiology
Genetics
Internal Medicine

Background:

Hypertrophic cardiomyopathies (HCM) are a diverse group of conditions causing left ventricular hypertrophy.
HCM etiology is varied, including genetic factors, metabolic disorders, and deposition diseases, distinct from pressure overload causes.
Non-specific cardiac signs necessitate a syndromic approach during clinical examination.

Purpose of the Study:

To summarize the heterogeneous nature of hypertrophic cardiomyopathies.
To outline diagnostic strategies for unexplained left ventricular hypertrophy.
To discuss current therapeutic approaches and risk stratification for HCM.

Main Methods:

Review of pathophysiological mechanisms and etiologies of HCM.
Description of diagnostic workup including ECG, echocardiography, MRI, and bone scintigraphy.
Consideration of genetic analysis and syndromic evaluation.

Main Results:

HCM diagnosis requires exploring causes beyond hypertension or aortic stenosis.
Diagnostic tools like echocardiography and MRI are essential for identifying underlying etiologies.
Specific treatments exist for conditions like amyloidosis and Fabry disease.

Conclusions:

Systematic etiological investigation is vital for unexplained left ventricular hypertrophy.
Genetic counseling and analysis should be routinely considered.
Risk stratification for arrhythmias and tailored symptomatic treatment are key management components.